SR ONE CAPITAL MANAGEMENT, LP
Q3 2026 13F-HR Holdings
Net value change ($000)
+110,532
(10.6%)
New positions
3
Sold out positions
1
Turnover %
19.2%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q2 2026
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| ADARx Pharmaceuticals, Inc. | 198,137 | NEW |
| Korsana Biosciences, Inc. | 19,645 | NEW |
| Odyssey Therapeutics, Inc. | 13,320 | 18.8% |
| ORIC | 12,184 | 24.4% |
| ZBIO | 8,010 | 6.3% |
| CRSP | 1,590 | 1.4% |
| ENGN | 1,496 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| MANE | -43,113 | -14.6% |
| ALMS | -40,667 | -73.7% |
| SPRY | -14,847 | -46.2% |
| Avalyn Pharma, Inc | -14,658 | -13.5% |
| DSGN | -12,400 | -13.1% |
| Mobia Medical, Inc | -7,845 | -29.5% |
| OCS | -2,904 | -32.7% |
| MLYS | -2,894 | -6.9% |
| RARE | -2,530 | -55.0% |
| ENGN | -1,294 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|